Kaposi Sarcoma (HHV-8)

Overview

Plain-Language Overview

Kaposi Sarcoma (HHV-8) is a type of cancer that affects the skin and other organs by causing abnormal growth of blood vessels. It primarily involves the skin, but can also affect the lymph nodes, lungs, and digestive tract. This condition is caused by infection with the human herpesvirus 8 (HHV-8), which leads to the formation of purple or brown patches, plaques, or nodules on the skin. These lesions may be painless but can sometimes cause swelling or discomfort. The disease mainly impacts the body's ability to maintain normal blood vessel function and can lead to complications if internal organs are involved. It is more common in people with weakened immune systems, such as those with HIV/AIDS. The presence of these skin changes is a key sign that prompts further medical evaluation.

Clinical Definition

Kaposi Sarcoma (HHV-8) is a vascular neoplasm characterized by the proliferation of spindle-shaped endothelial cells infected with human herpesvirus 8 (HHV-8). It manifests as multifocal lesions involving the skin, mucous membranes, lymph nodes, and visceral organs. The pathogenesis involves HHV-8-driven angiogenesis and inflammation, leading to the formation of characteristic violaceous plaques and nodules. It is classified into several epidemiologic forms: classic, endemic (African), iatrogenic (immunosuppression-associated), and epidemic (AIDS-related). The disease is significant due to its association with immunodeficiency, particularly in HIV-infected patients, where it represents an AIDS-defining illness. Histologically, lesions show spindle cell proliferation, neovascularization, and extravasated red blood cells. The clinical course varies from indolent to aggressive, depending on the host immune status and disease extent.

Inciting Event

Infection with human herpesvirus 8 (HHV-8) is the essential initiating event.
Immunosuppression triggers viral reactivation and tumor development.
HIV infection accelerates HHV-8 driven oncogenesis.

Latency Period

Latency from HHV-8 infection to lesion development can range from months to years depending on immune status.
In HIV patients, Kaposi sarcoma may develop within months after severe immunosuppression.
Classic Kaposi sarcoma often has a slow, indolent course over years before diagnosis.

Diagnostic Delay

Lesions may be mistaken for benign vascular lesions or bruises, delaying biopsy.
Lack of awareness in non-HIV immunosuppressed patients leads to missed diagnosis.
Early lesions are often painless and asymptomatic, causing patients to delay seeking care.

Clinical Presentation

Signs & Symptoms

Painless violaceous skin lesions that may progress in size and number.
Swelling or lymphedema of the extremities due to lymphatic obstruction.
Oral lesions causing discomfort or bleeding.
Respiratory symptoms such as cough or dyspnea if lungs are involved.
Gastrointestinal bleeding or abdominal pain with visceral involvement.

History of Present Illness

Patients typically report slowly progressive, painless violaceous skin lesions on the lower extremities or face.
Lesions may start as macules or plaques and evolve into nodules over weeks to months.
In advanced cases, patients may develop oral mucosal lesions, lymphedema, or visceral involvement causing systemic symptoms.

Past Medical History

HIV/AIDS diagnosis or other causes of immunosuppression such as organ transplantation.
History of immunosuppressive therapy including corticosteroids or chemotherapy.
Prior exposure to endemic regions with high HHV-8 prevalence.

Family History

No well-established heritable syndromes associated with Kaposi sarcoma.
Rare familial clustering reported in classic Kaposi sarcoma but no clear genetic mutations identified.

Physical Exam Findings

Multiple violaceous to dark red macules, plaques, or nodules primarily on the skin and mucous membranes.
Non-blanching lesions that may coalesce and have a patchy distribution.
Lymphedema of the affected limbs due to lymphatic obstruction.
Oral cavity involvement with purple lesions on the palate or gingiva.
Visceral lesions may be palpable as masses in advanced disease.

Diagnostic Workup

Diagnostic Criteria

Diagnosis of Kaposi Sarcoma relies on clinical recognition of characteristic violaceous skin lesions combined with histopathologic confirmation. A skin or tissue biopsy reveals spindle cell proliferation, slit-like vascular spaces, and HHV-8 positivity by immunohistochemical staining. Detection of HHV-8 DNA by PCR in lesion samples supports the diagnosis. Imaging and endoscopy may be used to assess visceral involvement. Definitive diagnosis requires correlation of clinical, histologic, and virologic findings.

Pathophysiology

Key Mechanisms

HHV-8 infection induces proliferation of vascular endothelial cells leading to angiogenesis and spindle cell tumor formation.
Viral oncogenes from HHV-8 promote cell cycle dysregulation and inhibit apoptosis.
Chronic inflammation and immunosuppression facilitate unchecked viral replication and tumor growth.
Cytokine release (e.g., VEGF) drives angioproliferation and lesion expansion.

Involvement	Details
Organs	Skin is the most frequently affected organ, presenting with characteristic lesions in Kaposi sarcoma.
	Lymph nodes may be infiltrated by tumor cells, causing lymphadenopathy and systemic symptoms.
	Lungs can be involved in disseminated disease, leading to respiratory symptoms and impaired function.
Tissues	Dermal tissue is commonly involved in Kaposi sarcoma, where characteristic violaceous plaques and nodules develop.
	Lymphatic tissue is affected, contributing to lymphedema and tumor spread in advanced disease.
	Mucosal tissue involvement occurs in oral and gastrointestinal sites, leading to ulcerations and bleeding.
Cells	Endothelial cells are the primary neoplastic cells in Kaposi sarcoma, undergoing proliferation driven by HHV-8 infection.
	T cells play a critical role in controlling HHV-8 infection and tumor progression, with immunosuppression facilitating disease.
	Macrophages contribute to the tumor microenvironment by secreting cytokines that promote angiogenesis and tumor growth.
Chemical Mediators	Vascular endothelial growth factor (VEGF) is upregulated in Kaposi sarcoma, promoting angiogenesis and lesion development.
	Interleukin-6 (IL-6) is elevated and supports proliferation and survival of Kaposi sarcoma cells.
	HHV-8 viral proteins such as viral G protein-coupled receptor (vGPCR) induce proangiogenic and proliferative signaling pathways.

Treatments

Pharmacological Treatments

Liposomal doxorubicin
- Mechanism:
  - Intercalates DNA and inhibits topoisomerase II, causing DNA damage and apoptosis in Kaposi sarcoma cells.
- Side effects:
  - Myelosuppression
  - Cardiotoxicity
  - Alopecia
- Clinical role:
  - First-line
Paclitaxel
- Mechanism:
  - Stabilizes microtubules and inhibits mitosis, leading to apoptosis of Kaposi sarcoma tumor cells.
- Side effects:
  - Peripheral neuropathy
  - Myelosuppression
  - Hypersensitivity reactions
- Clinical role:
  - Second-line
Interferon-alpha
- Mechanism:
  - Enhances immune response and has antiproliferative effects on Kaposi sarcoma lesions.
- Side effects:
  - Flu-like symptoms
  - Depression
  - Myelosuppression
- Clinical role:
  - Adjunctive
Antiretroviral therapy (ART)
- Mechanism:
  - Suppresses HIV replication, restores immune function, and indirectly reduces HHV-8 driven tumor growth.
- Side effects:
  - Lipodystrophy
  - Hepatotoxicity
  - Hyperlipidemia
- Clinical role:
  - First-line

Non-pharmacological Treatments

Radiation therapy is used for localized Kaposi sarcoma lesions causing symptoms or cosmetic concerns.
Surgical excision may be performed for isolated cutaneous lesions to improve function or appearance.
Supportive care includes management of lymphedema and pain control in advanced disease.

Prevention

Pharmacological Prevention

Antiretroviral therapy (ART) to maintain immune function in HIV-positive patients.
Prophylactic antiviral agents are not established for HHV-8 but controlling HIV reduces risk.
Immunosuppressant dose reduction in transplant patients to prevent KS development.

Non-pharmacological Prevention

Safe sex practices to reduce HHV-8 and HIV transmission.
Regular HIV screening and early ART initiation in at-risk populations.
Minimizing immunosuppression when possible in transplant recipients.
Routine skin examinations in immunocompromised patients for early lesion detection.

Outcome & Complications

Complications

Progressive lymphedema leading to limb disfigurement and functional impairment.
Visceral organ dysfunction from tumor infiltration (lungs, GI tract).
Secondary infections in ulcerated or lymphedematous skin.
Hemorrhage from mucosal or gastrointestinal lesions.
Malignant transformation is rare but possible.

Short-term Sequelae	Long-term Sequelae
Rapid increase in lesion size or number during immunosuppression. Acute lymphedema causing pain and decreased mobility. Bleeding from friable mucocutaneous lesions. Respiratory distress if pulmonary involvement is significant.	Chronic lymphedema with fibrosis and skin changes. Permanent disfigurement from extensive skin lesions. Organ failure due to progressive visceral involvement. Increased risk of opportunistic infections due to underlying immunodeficiency.

Differential Diagnoses

Kaposi Sarcoma (HHV-8) versus Bacillary Angiomatosis

Kaposi Sarcoma (HHV-8)	Bacillary Angiomatosis
Infection with human herpesvirus 8 (HHV-8)	Infection with Bartonella henselae or Bartonella quintana
Spindle cell proliferation with slit-like vascular spaces and HHV-8 positivity on immunohistochemistry	Vascular proliferation with neutrophilic inflammation and presence of bacilli on Warthin-Starry stain
Requires antiretroviral therapy and chemotherapy or immunomodulatory agents	Rapid improvement with oral erythromycin or doxycycline

Kaposi Sarcoma (HHV-8) versus Pyogenic Granuloma

Kaposi Sarcoma (HHV-8)	Pyogenic Granuloma
Multiple, slowly progressive violaceous plaques or nodules	Rapidly growing, solitary, friable red papule or nodule often following trauma
Spindle cell proliferation with vascular slits and HHV-8 positivity	Lobular capillary hemangioma with prominent capillaries and edema
More common in immunocompromised adults	Common in children and young adults

Kaposi Sarcoma (HHV-8) versus Angiosarcoma

Kaposi Sarcoma (HHV-8)	Angiosarcoma
Spindle cells with mild atypia and HHV-8 positivity	Highly atypical endothelial cells with marked pleomorphism and mitotic figures
Indolent course with slow progression	Aggressive, rapidly enlarging tumor with early metastasis
Multiple cutaneous and mucosal lesions without deep tissue invasion initially	Ill-defined, infiltrative mass often involving deep soft tissues

Kaposi Sarcoma (HHV-8) versus Cutaneous T-cell Lymphoma (Mycosis Fungoides)

Kaposi Sarcoma (HHV-8)	Cutaneous T-cell Lymphoma (Mycosis Fungoides)
Proliferation of HHV-8 infected endothelial spindle cells	Clonal proliferation of malignant T lymphocytes
Violaceous plaques and nodules often on lower extremities and mucosa	Patches and plaques with scaling and pruritus, often on sun-protected areas
HHV-8 immunohistochemistry positive	T-cell receptor gene rearrangement positive

Kaposi Sarcoma (HHV-8) versus Melanoma

Kaposi Sarcoma (HHV-8)	Melanoma
Spindle cell proliferation with vascular channels and HHV-8 positivity	Atypical melanocytes with melanin pigment and positive S-100 and HMB-45 staining
Non-pigmented violaceous plaques or nodules	Pigmented lesion with asymmetry, border irregularity, color variation, and evolution
Positive HHV-8 immunostaining	Positive melanocytic markers (S-100, HMB-45)